Developer docs
API playgroundTry for free, no card

Search company profiles

Cardiome Pharma

Full company profile

uuid0006nx4

Namestring
Cardiome Pharma
Legal namestring
Not determinable from available source data
Websiteurl
cardiome.com
Company typeenum
Private
Founded yearint
1986
Descriptiontext

Cardiome Pharma is an entity operating under the cardiome.com web domain that, based on available input data, presents itself as a pharmaceutical company oriented toward the cardiovascular therapeutic area (as suggested by the 'Cardiome' naming convention combining 'cardio' and 'ome'). The company has not yet disclosed any operational substance: its website is a placeholder 'Launching Soon' page with only a 2025 copyright notice, a 'Contact Us' prompt, and a standard cookie consent banner. No products, pipeline assets, technology stack, regulatory filings, certifications, leadership team, headcount, funding history, partnerships, customer references, operating geographies, or revenue figures are documented in the input data.

Because the source material is limited to a single placeholder webpage, the company's actual business model, core products, underlying technology, pricing mechanics, go-to-market strategy, and customer segments cannot be verified from the available evidence. It is unknown whether Cardiome Pharma is a newly formed entity preparing to launch, a previously operating company undergoing a relaunch, a shell brand, or an entity whose substantive information simply has not been captured in the scraped source set. The only resolvable source ID consistently attributes the 'Launching Soon' placeholder observation to the cardiome.com landing page itself.

From an analytical standpoint, the company should be treated as a pre-commercial or pre-disclosure-stage entity pending further evidence. Any investment-grade conclusions about therapeutic focus, pipeline quality, regulatory pathway, commercial viability, or capital structure require confirmation from primary sources beyond the placeholder website, including clinical pipelines, FDA/EMA filings, investor disclosures, or corporate registries.

Short descriptiontext

Cardiome Pharma operates the cardiome.com domain, which displays only a 'Launching Soon' placeholder page with a 2025 copyright notice. The name suggests an intended focus on cardiovascular pharmaceuticals, but no products, customers, team, funding, or operations are documented in available data.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
51–100
akta.pro rankint
HeadquartersVancouver, Canada
HQ citystring
Vancouver
HQ countrystring
Canada
HQ regionstring
North America
Markets served

Serves global market

Product category
Pharmaceuticals
Social media profiles1 record
GTM typeB2B
B2B
Offering typeServices
Services
Core offering1 text field

The cardiome.com website displays only a "Launching Soon" placeholder page. No core offerings, products, or services are evidenced in the available source data.

Differentiator
Functional benefit
Problem solved
Recent move1 record

Each record includes

Date, Type, Title, Description, Source

Expansion highlight1 record

Each record includes

Type, Description

Peers6 records
TypeDirect peer
Description

Biopharmaceutical company developing treatments for cardiovascular and metabolic diseases. Comparable as a developer targeting overlapping cardio-metabolic indications with a specialty-pharma profile.

TypeDirect peer
Description

Clinical-stage biopharmaceutical company focused on cardio-metabolic and liver disease, with commercialized cardiovascular-relevant therapy. Comparable as a specialty pharma with therapeutic focus intersecting cardiovascular and metabolic disease.

TypeDirect peer
Description

Late-stage specialty biopharmaceutical company developing cardiac muscle biology-directed therapies for heart failure and related cardiovascular conditions. Comparable as a focused cardiac-muscle therapeutic developer in the cardiology space.

TypeEmerging player
Description

Clinical-stage biotechnology company focused on cardiac gene therapy and related regenerative approaches for heart disease. Comparable as a development-stage player working in the cardiology therapeutic space, though using a different modality.

TypeBroad incumbent
Description

Major pharmaceutical company with an established cardiovascular franchise (e.g., Xarelto/rivaroxaban). Comparable as a broad incumbent operating in the cardiology space where a focused specialty entrant would compete or partner.

TypeDirect peer
Description

Specialty cardiovascular pharmaceutical company focused on lipid management and cardiometabolic disease, with commercialized oral therapies. Highly comparable as a focused, public cardio-pharma entity targeting established cardiovascular indications.

Market position
Strengths2 records

Each record includes

Headline, Details, Source

Weaknesses3 records

Each record includes

Headline, Details, Source

Key risks4 records

Each record includes

Headline, Details, Source

Key highlights2 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

No data
Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Core technology
Revenue estimate
Valuation estimate
Number of profiles
No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds2 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors1 record

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Cardiome Pharma

Pharmaceuticalscardiome.com

Cardiome Pharma operates the cardiome.com domain, which displays only a 'Launching Soon' placeholder page with a 2025 copyright notice. The name suggests an intended focus on cardiovascular pharmaceuticals, but no products, customers, team, funding, or operations are documented in available data.

What Cardiome Pharma does

Cardiome Pharma is an entity operating under the cardiome.com web domain that, based on available input data, presents itself as a pharmaceutical company oriented toward the cardiovascular therapeutic area (as suggested by the 'Cardiome' naming convention combining 'cardio' and 'ome'). The company has not yet disclosed any operational substance: its website is a placeholder 'Launching Soon' page with only a 2025 copyright notice, a 'Contact Us' prompt, and a standard cookie consent banner. No products, pipeline assets, technology stack, regulatory filings, certifications, leadership team, headcount, funding history, partnerships, customer references, operating geographies, or revenue figures are documented in the input data.

Because the source material is limited to a single placeholder webpage, the company's actual business model, core products, underlying technology, pricing mechanics, go-to-market strategy, and customer segments cannot be verified from the available evidence. It is unknown whether Cardiome Pharma is a newly formed entity preparing to launch, a previously operating company undergoing a relaunch, a shell brand, or an entity whose substantive information simply has not been captured in the scraped source set. The only resolvable source ID consistently attributes the 'Launching Soon' placeholder observation to the cardiome.com landing page itself.

From an analytical standpoint, the company should be treated as a pre-commercial or pre-disclosure-stage entity pending further evidence. Any investment-grade conclusions about therapeutic focus, pipeline quality, regulatory pathway, commercial viability, or capital structure require confirmation from primary sources beyond the placeholder website, including clinical pipelines, FDA/EMA filings, investor disclosures, or corporate registries.

Cardiome Pharma firmographics

Firmographics
Name
Cardiome Pharma
Legal name
Not determinable from available source data
Website
https://cardiome.com
Company type
Private
Founded year
1986
Operating status
Operating
Headcount range
51–100 employees
Short description
Cardiome Pharma operates the cardiome.com domain, which displays only a 'Launching Soon' placeholder page with a 2025 copyright notice. The name suggests an intended focus on cardiovascular pharmaceuticals, but no products, customers, team, funding, or operations are documented in available data.
Ownership category
akta.pro rank

Where Cardiome Pharma is headquartered

Location

Headquarters

HQ city
Vancouver
HQ country
Canada
HQ region
North America

Markets served

Cardiome Pharma business model

Business model
GTM type
B2B
Offering type
Services

Cardiome Pharma product offering

Product offering

Core offering

The cardiome.com website displays only a "Launching Soon" placeholder page. No core offerings, products, or services are evidenced in the available source data.

Differentiator

Problem solved

Functional benefit

Cardiome Pharma technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Cardiome Pharma partnerships and signals

Strategic signal

Recent moves1 record

Expansion highlights1 record

Cardiome Pharma competitors and assessment

Company assessment

Direct peers

  • Lexicon Pharmaceuticals: Biopharmaceutical company developing treatments for cardiovascular and metabolic diseases. Comparable as a developer targeting overlapping cardio-metabolic indications with a specialty-pharma profile.
  • Madrigal Pharmaceuticals: Clinical-stage biopharmaceutical company focused on cardio-metabolic and liver disease, with commercialized cardiovascular-relevant therapy. Comparable as a specialty pharma with therapeutic focus intersecting cardiovascular and metabolic disease.
  • Cytokinetics: Late-stage specialty biopharmaceutical company developing cardiac muscle biology-directed therapies for heart failure and related cardiovascular conditions. Comparable as a focused cardiac-muscle therapeutic developer in the cardiology space.
  • Esperion Therapeutics: Specialty cardiovascular pharmaceutical company focused on lipid management and cardiometabolic disease, with commercialized oral therapies. Highly comparable as a focused, public cardio-pharma entity targeting established cardiovascular indications.

Emerging players

  • Tenaya Therapeutics: Clinical-stage biotechnology company focused on cardiac gene therapy and related regenerative approaches for heart disease. Comparable as a development-stage player working in the cardiology therapeutic space, though using a different modality.

Broad incumbents

  • Bayer (Cardiovascular Division): Major pharmaceutical company with an established cardiovascular franchise (e.g., Xarelto/rivaroxaban). Comparable as a broad incumbent operating in the cardiology space where a focused specialty entrant would compete or partner.

Market position

Strengths2 records

Weaknesses3 records

Key risks4 records

Key highlights2 records

Customer concentration

Cardiome Pharma social profiles

Digital presence

Cardiome Pharma financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Cardiome Pharma leadership team

Management profile

Number of profiles

Cardiome Pharma funding detail

Funding detail

Funding overview

Funding rounds2 records

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Cardiome Pharma M&A and investment

M&A and investment

M&A1 record

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Cardiome Pharma

What does Cardiome Pharma do?

The cardiome.com website displays only a "Launching Soon" placeholder page. No core offerings, products, or services are evidenced in the available source data.

When was Cardiome Pharma founded?

Cardiome Pharma was founded in 1986. It employs 51 to 100 people.

Where is Cardiome Pharma based?

Cardiome Pharma is headquartered in Vancouver, Canada, in the North America region.

Who are Cardiome Pharma's main competitors?

Direct peers on record are Lexicon Pharmaceuticals, Madrigal Pharmaceuticals, Cytokinetics and Esperion Therapeutics. Tenaya Therapeutics is listed as an emerging player. Bayer (Cardiovascular Division) is listed as a broad incumbent.

Does Cardiome Pharma have an API?

No public API is recorded for Cardiome Pharma.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
PR NewswireCardiome Announces Results From Annual and Special Meeting of Shareholders and Timing For First Quarter 2018 Financial Results Conference CallCardiome Pharma Corp. held its Annual and Special Meeting of Shareholders on May 10, 2018, in Vancouver, Canada, where all six board nominees were elected with strong shareholder support. Shareholders approved, by approximately 99.93% of votes cast, a special resolution permitting Cipher Pharmaceuticals to acquire Cardiome's Canadian business portfolio, including Brinavess, Aggrastat, Xydalba, and Trevyent, as part of a planned corporate restructuring that will transfer Cardiome's outstanding shares to newly created subsidiary Correvio Pharma Corp.PR NewswireCardiome Completes Enrollment in the Post Approval Safety Study SPECTRUM Evaluating Brinavess®Cardiome Pharma Corp. announced completion of enrollment for its Phase 4 SPECTRUM post-authorization safety study evaluating Brinavess (vernakalant hydrochloride, IV), an antiarrhythmic drug for rapid conversion of recent onset atrial fibrillation. The observational registry enrolled 2,000 patients in the European Union to characterize normal conditions of use, dosing, and safety in real-world clinical practice settings. The full clinical study report is expected to be available in Q3 2018, with Cardiome planning to publish the data to fulfill EU post-marketing commitments.PR NewswireCardiome Announces Amendment to Term Loan Agreement with CRG-Managed FundsCardiome Pharma Corp. entered into an amending agreement with CRG Servicing LLC to adjust financial covenants regarding minimum revenue requirements. As part of this agreement, CRG waived up to $6 million in cash compensation and permitted the divestiture of Cardiome's Canadian business portfolio to Cipher Pharmaceuticals, while receiving 800,000 common share purchase warrants in consideration.PR NewswireCardiome Highlights Partner SteadyMed's Progress Towards Trevyent NDA ResubmissionCardiome Pharma Corp. announced that its partner SteadyMed Therapeutics is progressing toward resubmission of a New Drug Application for Trevyent to the FDA by end of 2018, following favorable feedback from an in-person Type A meeting. The FDA confirmed no further clinical trials are required and that pre-design verification tests on the final product would be adequate for acceptance under the 505(b)(2) pathway. Cardiome plans to submit regulatory filings for Trevyent in Europe and Canada shortly after SteadyMed's NDA resubmission.PR NewswireCardiome Announces Recent Insider PurchasesCardiome Pharma Corp. announced that its President and CEO Dr. William Hunter and CFO Justin Renz purchased a combined 210,000 common shares of the company on March 26, 2018. These insider purchases were executed on both the TSX and NASDAQ exchanges for investment purposes. The transactions were disclosed via the System for Electronic Disclosure by Insiders (SEDI).PR NewswireHealth Canada Accepts Cardiome's Xydalba New Drug Submission and Grants Priority ReviewHealth Canada has accepted Cardiome Pharma Corp.'s New Drug Submission for Xydalba (dalbavancin hydrochloride) and granted it Priority Review status, with an approval decision expected in Q3 2018. Priority Review shortens the standard 300-day review timeline to approximately 180 days for medicines addressing life-threatening or severely debilitating conditions. A proposed strategic transaction would see Cipher Pharmaceuticals Inc. acquire Canadian commercial rights to Xydalba upon closing.PR NewswireCardiome to Hold Fourth Quarter and Full Year 2017 Financial Results Conference Call on March 13Cardiome Pharma Corp. announced it will report financial results for the fourth quarter and full year ended December 31, 2017 on March 13, 2018. The company will hold a conference call and webcast at 4:30 p.m. Eastern Time the same day to discuss the results, accessible via dial-in numbers and webcast link provided in the announcement. Cardiome is a revenue-generating specialty pharmaceutical company focused on commercializing hospital drugs with a commercial presence in over 60 countries.PR NewswireCardiome Announces Expanded Label for Aggrastat® in China Including New STEMI Indication and High Dose Bolus RegimenCardiome Pharma Corp. announced that China's Center for Drug Evaluation (CDE) has approved an expansion of the indications for Aggrastat (tirofiban hydrochloride) to include ST-segment elevation myocardial infarction (STEMI) patients undergoing primary PCI, in addition to the existing non-ST elevation acute coronary syndrome (NSTE-ACS) indication. The CDE also approved a high dose bolus (HDB) regimen that aligns Chinese dosing with U.S., European, and Canadian standards. Eddingpharm, Cardiome's commercial partner in China, will execute the expanded label, significantly broadening the patient population eligible for Aggrastat in a market where the drug was previously limited to NSTE-ACS and angioplasty prevention.PR NewswireCardiome Announces Strategic Licensing Agreement To Commercialize Aggrastat In RussiaCardiome Pharma Corp.'s affiliate Correvio has entered into an exclusive license and distribution agreement with ZAO Firma Euroservice to commercialize Aggrastat (tirofiban hydrochloride) in Russia. Under the terms, ZAO will be responsible for obtaining regulatory approvals from Russia's Ministry of Health, then executing the commercial launch and subsequent sale and marketing of the medication. Aggrastat is currently marketed in over 60 countries worldwide and is used to reduce thrombotic cardiovascular events in patients with acute coronary syndrome.PR NewswireCardiome Announces Xydalba™ Treatment And Patient Experience Presentations At The 2017 National Opat ConferenceCardiome Pharma Corp. announced a plenary symposium at the 2017 National OPAT Conference in Birmingham, UK, where expert physicians will discuss the clinical use of Cardiome's treatment Xydalba™ for acute bacterial skin infections. The symposium features key presentations focused on patient experience and treatment management. This highlights Cardiome's commitment to advancing knowledge and use of its innovative therapies in a clinical setting.